Stock Analysis of Mink Therapeutics Inc (INKT) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code INKT
Close 1.01
Change 0 / 0 %
Volume 28086.00
Vol Change -40678.00 / 59.16 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Very Low Profitability Stock
Stability Index Good Stability


Fundamental View of Mink Therapeutics Inc
PE (TTM)

-0.0023

Very Poor
Price / Book

-0.0267

Very Poor
Price / Sales

-0.0030

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

35051.04 K

Enterprise Value

31683.81 K

ROA (TTM)

-285.63

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

129.24

Excellent
Revenue

100.00 %

0
Net Profit

11.51 %

-24769.00 K
Debt to Equity

0

Excellent
Altman Z Score

-60.12

Very Poor
Quick Ratio

0

Poor
Cash Ratio

0.295

Poor


Highs/Lows of Mink Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.9798 3.08 % 1.74 % 1.30.931115-May-2415-May-24
Two Week0.9407 7.37 % 2.54 % 1.30.8615-May-2409-May-24
One Month0.8763 15.26 % 6.94 % 1.30.8615-May-2409-May-24
Three Month0.9389 7.57 % 6.77 % 1.90.7805-Apr-2420-Mar-24
Six Months1.06 4.72 % 16.82 % 1.90.7505-Apr-2416-Jan-24
One year1.78 43.26 % 26.72 % 3.340.7522-Jun-2316-Jan-24
Two year1.31 22.90 % 36.16 % 3.420.7514-Nov-2216-Jan-24


Technical View of Mink Therapeutics Inc
RSI

53.28

Neutral
MACD

0.0172

Bullish
ADX

36.05

Bullish
Super Trend

0.797

Mild Bullish
Williams %R

-65.91

Neutral
CCI

74.41

Neutral


EMA 5

1.02

Bearish
EMA 15

0.988

Bullish
EMA 50

0.969

Bullish
EMA 100

0.998

Strong Bullish
SMA 100

0.954

Whipsaw
SMA 200

1.09

Whipsaw
SMA 5 / 20

1.04 / 0.960

Strong Bullish
SMA 15 / 50

0.979 / 0.965

Bullish
SMA 50 / 200

0.965 / 1.09

Mild Bearish




Charts of Mink Therapeutics Inc


Returns of Mink Therapeutics Inc with Peers
Period / StockINKTOWLTACXPPMN
1 Week3.08%-2.50%6.70%-7.76%
1 Mth15.26%1.04%10.95%-5.39%
3 Mth7.57%-13.33%-23.63%-1.61%
6mth-4.72%-34.34%-38.40%28.12%
1 Year-43.26%8.60%-26.40%-67.06%
2 Year-22.90%-92.33%-15.53%-99.40%
5 Years----99.74%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Mink Therapeutics Inc with Peers
Ratio / StockINKTOWLTACXPPMN
PE-0.0023-369705.94-0.665-2.92
P/B-0.0267-420460.681.6947.11
ROA-285.63-59.61-166.33-74.62
ROE00-254.90-1614.61
Debt To Equity0-0.51200
Revenue0
100.00 % 		800000
1056.07 % 		0
% 		0
100.00 %
Net Income-24769.00 K
11.51 % 		-32900.00 K
45030.32 % 		-12723.69 K
5.21 % 		-16897.56 K
6.45 %


Technicals of Mink Therapeutics Inc with Peers
Technical / StockINKTOWLTACXPPMN-
ADX36.0514.7017.2122.91
CMF-0.369-0.2430.00510.135
MFI91.2435.8055.8032.88
RSI53.2844.0255.8345.27
MACD Abv SignalTrueFalseTrueFalse
Price Above 50 MATrueFalseTrueFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Mink Therapeutics Inc

Address : 149 Fifth Avenue, New York, NY, United States, 10010
Tel : 212 994 8250
URL : https://minktherapeutics.com
Code : INKT, ISIN : US6036931029, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 15_Oct_2021
Employee Count : 31

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.


Note : All Data Generated at the End of Trading Hours (EOD Data)